FDA’s Drug Monitoring Slammed in Report
GAO: Post-Vioxx Scandal, Agency Gives Decision-Making Power to Wrong Scientists
December 9, 2009
U.S. court to hear Merck appeal on Vioxx investor suit
The U.S. Supreme Court said on Tuesday that it would hear an appeal by Merck & Co Inc of a ruling that reinstated a securities fraud lawsuit involving the company's disclosures to investors about its withdrawn Vioxx pain drug.
Merck wraps up defense in N.J. Vioxx case
Merck & Co. wrapped up its defense in the latest Vioxx product liability trial on Thursday with testimony from a psychiatrist who said one of the plaintiffs who blames the painkiller for his heart attack never mentioned taking it when discussing his medical history.
FDA panel narrowly approves Vioxx, but cites risk in drug category
A US health advisory panel confirmed cardiovascular risks from certain anti-inflammatory drugs, but agreed to the return of Vioxx, withdrawn last year, and continued sale of two similar medications whose safety was questioned.
